EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond

Othman Al Musaimi

Journal of Peptide Science · 17.06.2024

DOI: 10.1002/psc.3627 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Peptide Science, online erschienen am 17.06.2024. Verfasst von Othman Al Musaimi. Beteiligte Einrichtung: School of Pharmacy, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Cardiovascular Diseases, United States Food and Drug Administration, Drug Approval, Central Nervous System Diseases. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peptides exhibit significant specificity and effective interaction with therapeutic targets, positioning themselves as key players in the global pharmaceutical market. They offer potential treatments for a wide range of diseases, including those that pose significant challenges. Notably, the peptide trofinetide (Daybue) marked a groundbreaking achievement by providing the first‐ever cure for Rett syndrome, and several peptides have secured FDA approval as first‐in‐class medications. Furthermore, peptides are expanding their presence in areas traditionally dominated by either small or large molecules. A noteworthy example is the FDA approval of motixafortide (Aphexda) as the first peptide‐based chemokine antagonist. Here, the focus will be on the analysis of FDA‐approved peptides, particularly those targeting cardiovascular diseases, human immunodeficiency, central nervous system diseases, and various other intriguing classes addressing conditions such as osteoporosis, thrombocytopenia, Cushing's disease, and hypoglycemia, among others. The review will explore the chemical structures of the peptides, their indications and modes of action, the developmental trajectory, and potential adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesUnited States Food and Drug AdministrationDrug ApprovalCentral Nervous System DiseasesPeptidesHumansUnited StatesHIV Infections

Stichwörter der Autor:innen

CICCNSHIVPeptidesRDSSBScardiovasculardiagnosisosteoporosis

Substanzen

Peptides

Autor:innen und Institutionen

  • School of Pharmacy, Newcastle upon Tyne, UK.
  • Department of Chemical Engineering, Imperial College London, London, UK.

Zitieren

APA

Al Musaimi, O. (2024). FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond. Journal of Peptide Science. https://doi.org/10.1002/psc.3627

Vancouver

Al Musaimi O. FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond. Journal of Peptide Science. 2024. doi:10.1002/psc.3627

BibTeX
@article{AlMusaimi2024,
  author = {Al Musaimi, Othman},
  title = {FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond},
  journal = {Journal of Peptide Science},
  year = {2024},
  doi = {10.1002/psc.3627}
}
Kostenlos starten →